Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.
Waldenström J, Färkkilä M, Rembeck K, Norkrans G, Langeland N, Mørch K, Pedersen C, Rauning Buhl M, Nieminen U, Nuutinen H, Alsiö Å, Holmström L, Jungnelius R, Lund K, Rubensson A, Torell E, Westin J, Lagging M. Waldenström J, et al. Among authors: alsio a. Scand J Gastroenterol. 2016 Mar;51(3):337-43. doi: 10.3109/00365521.2015.1087588. Epub 2015 Sep 29. Scand J Gastroenterol. 2016. PMID: 26418670 Free PMC article. Clinical Trial.
Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection.
Pedersen C, Alsiö Å, Lagging M, Langeland N, Färkkilä M, Buhl MR, Mørch K, Westin J, Sangfelt P, Norkrans G, Christensen PB; NORDynamicIC Study Group. Pedersen C, et al. Among authors: alsio a. J Viral Hepat. 2011 Apr;18(4):245-51. doi: 10.1111/j.1365-2893.2010.01303.x. J Viral Hepat. 2011. PMID: 20384961 Clinical Trial.
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.
Alsiö A, Jannesson A, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Westin J, Hellstrand K, Norkrans G, Lagging M; NORDynamIC Study Group. Alsiö A, et al. Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1631-5. doi: 10.1007/s10096-011-1486-5. Epub 2011 Nov 24. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22113307
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.
Alsiö Å, Rembeck K, Askarieh G, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Haagmans BL, Nasic S, Westin J, Hellstrand K, Norkrans G, Lagging M. Alsiö Å, et al. PLoS One. 2012;7(5):e37521. doi: 10.1371/journal.pone.0037521. Epub 2012 May 24. PLoS One. 2012. PMID: 22655053 Free PMC article. Clinical Trial.
Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Christensen P, Leutscher P, Norkrans G; NORDynamIC Study Group. Lagging M, et al. Among authors: alsio a. Hepatology. 2008 Aug;48(2):695. doi: 10.1002/hep.22450. Hepatology. 2008. PMID: 18666232 No abstract available.
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.
Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M; DITTO-HCV and NORDynamIC Study Groups. Askarieh G, et al. Among authors: alsio a. Hepatology. 2010 May;51(5):1523-30. doi: 10.1002/hep.23509. Hepatology. 2010. PMID: 20186843 Clinical Trial.
19 results